Literature DB >> 3632552

Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval.

H J Altman, W S Stone, S O Ogren.   

Abstract

A total of three experiments were conducted. In Experiment 1, the dose-dependent effects of the pretest administration of the serotonergic agonist alaproclate and the selective muscarinic cholinergic agonist oxotremorine, alone and in combination, were assessed in a one-trial inhibitory avoidance task. A clear dose-dependent enhancement of performance was demonstrated as a result of all three treatment conditions, which could not be explained in terms of nonspecific effects of the drugs on behavior in general. In addition, the facilitation of retrieval performance produced by the combined treatment of alaproclate and oxotremorine was observed at dose levels well below those observed following administration of either compound alone. In Experiment 2 attempts were made to block the enhancements of retention resulting from the different treatment conditions (alaproclate, oxotremorine, or the combination of alaproclate and oxotremorine) by pretreating the mice with either scopolamine (a muscarinic cholinergic antagonist) or quipazine (a serotonergic agonist). The results of these experiments indicate that (a) quipazine completely blocked the enhancement of retrieval resulting from alaproclate but not that following oxotremorine or oxotremorine in combination with alaproclate, while (b) scopolamine blocked the enhancement of retrieval resulting from oxotremorine alone as well as that resulting from alaproclate plus oxotremorine but failed to block the memory enhancement resulting from alaproclate. The present results lend further support to the view that both serotonin and acetylcholine play important roles in memory retrieval. More importantly, the results of the present series of experiments provide additional support for a functional interaction between the serotonergic and cholinergic nervous systems in the mediation of behavior.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3632552     DOI: 10.1016/s0163-1047(87)90574-7

Source DB:  PubMed          Journal:  Behav Neural Biol        ISSN: 0163-1047


  16 in total

1.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Memory modulation.

Authors:  Benno Roozendaal; James L McGaugh
Journal:  Behav Neurosci       Date:  2011-12       Impact factor: 1.912

4.  Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain.

Authors:  H Soininen; L Unni; S Shillcutt
Journal:  Neurochem Res       Date:  1990-12       Impact factor: 3.996

5.  Effects of oxotremorine on inhibitory avoidance behaviour in two inbred strains of mice: interaction with 5-methoxy-NN-dimethyltriptamine.

Authors:  F Pavone; S Fagioli; C Castellano
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

7.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

8.  Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.

Authors:  J T Little; A Broocks; A Martin; J L Hill; L E Tune; C Mack; M Cantillon; S Molchan; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

9.  Potentiation of oxotremorine-induced hypothermia by alaproclate in PCA lesioned and non-lesioned rats.

Authors:  S C Dilsaver; H J Normile; H J Altman
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.

Authors:  Gwenn S Smith; Elisse Kramer; Yilong Ma; Carol R Hermann; Vijay Dhawan; Thomas Chaly; David Eidelberg
Journal:  Brain       Date:  2009-01-19       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.